<pre id="ka1bc"></pre>
    <table id="ka1bc"><noscript id="ka1bc"></noscript></table>
  1. <td id="ka1bc"></td>

    新聞中心
    公司新聞
    唯可達生物科技公司近兩年發表的文章

    1) Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine. CLIN INFECT DIS 2012; 54:17-24. (IF=9.15).

    2) Safe pseudovirus-based assay for neutralization antibodies against influenza A(H7N9) virus. EMERG INFECT DIS 2013; 19:1685-7. (IF=6.994) 

    3) Kinetics of serological responses in influenza A(H7N9)-infected patients correlate with clinical outcome in China, 2013. Euro Surveill 2013; 18:20657. (IF=5.983)

    4) Sequential immunization with consensus influenza hemagglutinins raises cross-reactive neutralizing antibodies against various heterologous HA strains. VACCINE 2017 2017-01-05;35(2):305-12.

    5) Induction of Broadly Cross-Reactive Stalk-Specific Antibody Responses to Influenza Group 1 and Group 2 Hemagglutinins by Natural H7N9 Virus Infection in Humans. J INFECT DIS 2017 2017-02-15;215(4):518-28. (IF=6.344)

    6) 表達甲型H1N1流感病毒血凝素抗原的DNA疫苗構建及其免疫原性評價.國際生物制品學雜志.34(03): 121-125. 2011.

     

    查看詳情
    唯可達生物科技公司承擔的國家和省級課題

    課題名稱:新型結核桿菌DNA疫苗的研制。江蘇省自然科學基金(課題號:BK2009603)。

    課題名稱:HIV-1 AE亞型人用DNA疫苗研制及臨床報批。江蘇省科技支撐計劃(課題號:BE2010661)。

    課題名稱:流感病毒的廣譜中和抗體研究。江蘇省自然科學基金(課題號:BK2011344)。

    查看詳情
    精品国产高清在线看国产毛片

      <pre id="ka1bc"></pre>
      <table id="ka1bc"><noscript id="ka1bc"></noscript></table>
    1. <td id="ka1bc"></td>